<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302106</url>
  </required_header>
  <id_info>
    <org_study_id>CLO2009AISSM05</org_study_id>
    <secondary_id>EudraCT number 2009-012755-23</secondary_id>
    <nct_id>NCT01302106</nct_id>
  </id_info>
  <brief_title>Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes</brief_title>
  <acronym>CLO2009AISSM05</acronym>
  <official_title>Phase II Study of Clofarabine in Combination With Low Dose Cytarabine for Untreated Patients With Poor Risk Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Sindromi Mielodisplastiche Onlus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Sindromi Mielodisplastiche Onlus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, multicenter, open label, phase II study designed to evaluate the
      safety and efficacy of Clofarabine in combination with low dose Cytarabine in untreated
      patients with poor risk of Myelodisplastic Syndromes.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    For increased induction mortality in older patients due to specific combinations of drugs,
    other clinical factors such as patient age and comorbidities.
  </why_stopped>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the remission rate according to the combination regimen</measure>
    <time_frame>19 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response and survival</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to transformation in AML</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the relationship of cytogenetic abnormalities and response to treatment</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety and tolerability of the combination regimen</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clofarabine combined with low dose Ara-C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine plus low dose Ara-C</intervention_name>
    <description>Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients age 55 to 80 years

          -  Written informed consent to participate in the clinical trial

          -  Morphologically confirmed diagnosis of MDS according to WHO classification, and IPSS
             INT-2 or high risk according to IPSS index

          -  ECOG performance status 0-2

          -  No previous chemotherapy

          -  Serum bilirubin ≤1.5 times upper limit of normal (ULN) (unless elevation is due
             primarily to elevated unconjugated hyperbilirubinemia secondary to Gilbert's syndrome
             or hemolysis, but not to liver dysfunction)

          -  AST and ALT ≤2.5 times ULN

          -  Alkaline phosphatase ≤2.5 times ULN

          -  Serum creatinine ≤ 1 mg/dl: if serum creatinine &gt; 1.0 mg/dl, then the estimated
             glomerular filtration rate (GFR) must be &gt;60 mL/min/1.73 m2 as calculated by the
             Modification of Diet in Renal Disease equation where Predicted GFR (ml/min/1.73 m2) =
             186 x (Serum Creatinine) -1.154 x age in years -0-023 x 0.742 (if patient is female) x
             1.212 (if patient is black)

          -  HIV negative

        Exclusion Criteria:

          -  Have had any other chemotherapy or any investigational therapy as a treatment for MDS.
             Patients who received chemotherapy for other cancers than MDS/AML can be enrolled,
             provided that at least 6 months elapsed from accomplishment of the last course of
             chemo.

          -  Have had a prior hematopoietic stem cell transplant for MDS

          -  Have an uncontrolled systemic fungal, bacterial, viral, or other infection (defined as
             exhibiting ongoing signs/symptoms related to the infection and without improvement,
             despite appropriate antibiotics or other treatment).

          -  Have a psychiatric disorder that would interfere with consent, study participation, or
             follow-up.

          -  Have any other severe concurrent disease, or have a history of serious organ
             dysfunction or disease involving the heart

          -  Have had any prior treatment with Clofarabine

          -  Have had a diagnosis of another malignancy, unless the patient has been disease-free
             for at least 3 years following the completion of curative intent therapy with the
             following exceptions: a.)Patients with treated non-melanoma skin cancer, in situ
             carcinoma, or cervical intraepithelial neoplasia, regardless of the disease -free
             duration, are eligible for this study if definitive treatment for the condition has
             been completed. b.)Patients with organ-confined prostate cancer with no evidence of
             recurrent or progressive disease based on prostate-specific antigen (PSA) values are
             also eligible for this study if hormonal therapy has been initiated or a radical
             prostatectomy has been performed.

          -  Have prior positive test for the Human Immunodeficiency Virus (HIV), HCV, HBV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felicetto Ferrara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Hematology and Stem Cell Transplantation Unit, Ospedale &quot;A.Cardarelli&quot;, Napoli, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SC Ematologia-AO SS.Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Scienze Mediche e Chirurgiche-Ospedale di Torrette</name>
      <address>
        <city>Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia con trapianto-AO Policlinico Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC di Ematologia-Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>centro di ricerca e di formazione ad alta tecnologia nelle Scienze-Università Cattolica Campobasso</name>
      <address>
        <city>Campobasso</city>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e Trapianto di Midollo Osseo-Ospedale Ferrarotto Alessi</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di medicina Interna-Università di genova</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia-Azienda Ospedaliero Papardo</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia-Ospedale San gennaro-ASL1</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia e Trapianto Cellule Staminali-Ospedale A.Cardelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicina interna II- Azienda Ospedaliera S.Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia-Ospedale Vincenzo Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Ematologia-Ospedale Spirito Santo Pescara</name>
      <address>
        <city>Pescara</city>
        <zip>65100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia- Azienda Ospedaliera Pisana Ospedale &quot;S.Chiara&quot;</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia- AO Bianchi Melacrino Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia e Trapianto Cellule Staminali, IRCCS, Centro di Riferimento Oncologico della Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <zip>85028</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia-Azienda Ospedaliera Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia, Centro Trapianto di cellule staminali-IRCCS &quot;Casa Sollievo della Sofferenza&quot;</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia 2-Ospedale San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia-Ospedale Cardinale Panico</name>
      <address>
        <city>Tricase</city>
        <zip>73039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2010</study_first_submitted>
  <study_first_submitted_qc>February 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>September 30, 2013</last_update_submitted>
  <last_update_submitted_qc>September 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Clofarabine</keyword>
  <keyword>Low Dose Cytarabine</keyword>
  <keyword>Poor risk MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

